The 6th annual European Antibody Congress is the
industry's largest and most influential monoclonal antibody conference
The 6th annual European Antibody Congress is the World's
leading conference addressing critical scientific issues and strategic industry
challenges associated with therapeutic mAb development.
New for 2010
* New market success stories: golimumab, canakinumab,
obatumumab, farletuzmab and girentuximab case studies
* For the first time on the agenda: Amgen, the FDA,
Chugai Pharmaceutical Co, sanofi-aventis, Sandoz, Merrimack* Pharmaceuticals, AdAlta, Wilex, Vaccinex
and Biocon
* First ever discussion of global biosimilar antibody
development and impact on the European market
* Exploring radio-immunoconjugates: scientific,
technical, regulatory and logistical challenges
* Spectacular boat cruise on board Lake Geneva
2010 key speakers include:
* Dr Andrew Goodearl, Director Bioresearch Center, Abbott
Laboratories
* Dr Veronique Blanc, Head of Cancer Biology, Biologics,
sanofi-aventis
* Dr Andrew Erdman, Global Safety Medical Director, Amgen
* Dr Mark McCamish, Head Global Pharmaceutical
Development, Sandoz
* Dr Clive Wood, Senior Vice President and Head of Global
Biologics, Bayer Schering Pharma
* Dr Alain Beck, Head of Physico-Chemistry Department,
Centre d'Immunology Pierre Fabre
* Dr Scott Glaser, Director, Antibody Therapeutics,
Biogen Idec
* Dr Sandeep Kumar, Principal Scientist, Global Biologics
Pharmaceutical Sciences R&D, Pfizer Global R&D
* Dr Victor Obungu, Senior Research Scientist,
Biotechnology Discovery Research, Eli Lilly & Co
* Dr Pablo Umana, Head of Research, Roche Glycart
Conferences 